---
document_datetime: 2023-09-21 20:56:33
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/byannli-previously-paliperidone-janssen-cilag-international-epar-all-authorised-presentations_en.pdf
document_name: byannli-previously-paliperidone-janssen-cilag-international-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8490733
conversion_datetime: 2025-12-17 08:58:32.302326
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                        | Route of Administration   | Immediate Packaging      | Pack size                       |
|------------------|-------------------|------------|--------------------------------------------|---------------------------|--------------------------|---------------------------------|
| EU/1/20/1453/007 | BYANNLI           | 700 mg     | Prolonged-release suspension for injection | Intramuscular use         | pre-filled syringe (COC) | 1 pre-filled syringe + 1 needle |
| EU/1/20/1453/008 | BYANNLI           | 1 000 mg   | Prolonged-release suspension for injection | Intramuscular use         | pre-filled syringe (COC) | 1 pre-filled syringe + 1 needle |